Evaluation of the pharmacokinetics and cardiotoxicity of doxorubicin in rat receiving nilotinib

Toxicology and Applied Pharmacology

Volumn 272, Issue 1, 2013, Pages 238-244

  Zhou, Zhi yong ^a   Wan, Li li ^a   Yang, Quan jun ^a   Han, Yong long ^a   Li, Yan ^a   Yu, Qi ^a   Guo, Cheng ^a   Li, Xiao ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Cardiotoxicity; Disposition; Doxorubicin; Nilotinib; P Glycoprotein; Pharmacokinetic

Indexed keywords

CREATINE KINASE; DOXORUBICIN; DOXORUBICINOL; LACTATE DEHYDROGENASE; MALONALDEHYDE; NILOTINIB; SUPEROXIDE DISMUTASE; VERAPAMIL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CARDIOTOXICITY; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG TISSUE LEVEL; HEART; HISTOPATHOLOGY; HUMAN; HUMAN CELL; LACTATE DEHYDROGENASE BLOOD LEVEL; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; RAT; SINGLE DRUG DOSE; STEADY STATE; TANDEM MASS SPECTROMETRY; TISSUE HOMOGENATE;

CARDIOTOXICITY; DISPOSITION; DOXORUBICIN; NILOTINIB; P-GLYCOPROTEIN; PHARMACOKINETIC;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; AREA UNDER CURVE; BIOLOGICAL MARKERS; CELL LINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOXORUBICIN; HEART DISEASES; MALE; MYOCARDIUM; P-GLYCOPROTEINS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; RATS; RATS, SPRAGUE-DAWLEY; TANDEM MASS SPECTROMETRY;

EID: 84883323254     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2013.06.002     Document Type: Article

References (37)

1. Booser D.J., Hortobagyi G.N. Anthracycline antibiotics in cancer therapy. Focus on drug resistance. Drugs 1994, 47:223-258.
2. Budde T., Haney J., Bien S., Schwebe M., Riad A., Tschope C., Staudt A., Jedlitschky G., Felix S.B., Kroemer H.K., Grube M. Acute exposure to doxorubicin results in increased cardiac P-glycoprotein expression. J. Pharm. Sci. 2011, 100:3951-3958.
3. Choi C.H. ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal. Cancer Cell Int. 2005, 5:30.
4. Estevez M.D., Wolf A., Schramm U. Effect of PSC 833, verapamil and amiodarone on adriamycin toxicity in cultured rat cardiomyocytes. Toxicol. In Vitro 2000, 14:17-23.
5. Golemovic M., Verstovsek S., Giles F., Cortes J., Manshouri T., Manley P.W., Mestan J., Dugan M., Alland L., Griffin J.D., Arlinghaus R.B., Sun T., Kantarjian H., Beran M. AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia. Clin. Cancer Res. 2005, 11:4941-4947.
6. Gottesman M.M., Pastan I., Ambudkar S.V. P-glycoprotein and multidrug resistance. Curr. Opin. Genet. Dev. 1996, 6:610-617.
7. Gottesman M.M., Fojo T., Bates S.E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer 2002, 2:48-58.
8. Hegedus C., Ozvegy-Laczka C., Apati A., Magocsi M., Nemet K., Orfi L., Keri G., Katona M., Takats Z., Varadi A., Szakacs G., Sarkadi B. Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties. Br. J. Pharmacol. 2009, 158:1153-1164.
9. Hu X.F., Slater A., Wall D.M., Kantharidis P., Parkin J.D., Cowman A., Zalcberg J.R. Rapid up-regulation of mdr1 expression by anthracyclines in a classical multidrug-resistant cell line. Br. J. Cancer 1995, 71:931-936.
10. Huang W., Ding L., Huang Q., Hu H., Liu S., Yang X., Hu X., Dang Y., Shen S., Li J., Ji X., Jiang S., Liu J.O., Yu L. Carbonyl reductase 1 as a novel target of (-)-epigallocatechin gallate against hepatocellular carcinoma. Hepatology 2010, 52:703-714.
11. Huls M., Russel F.G., Masereeuw R. The role of ATP binding cassette transporters in tissue defense and organ regeneration. J. Pharmacol. Exp. Ther. 2009, 328:3-9.
12. Iqbal M., Dubey K., Anwer T., Ashish A., Pillai K.K. Protective effects of telmisartan against acute doxorubicin-induced cardiotoxicity in rats. Pharmacol. Rep. 2008, 60:382-390.
13. Jungsuwadee P., Nithipongvanitch R., Chen Y., Oberley T.D., Butterfield D.A., St Clair D.K., Vore M. Mrp1 localization and function in cardiac mitochondria after doxorubicin. Mol. Pharmacol. 2009, 75:1117-1126.
14. Kitazaki T., Oka M., Nakamura Y., Tsurutani J., Doi S., Yasunaga M., Takemura M., Yabuuchi H., Soda H., Kohno S. Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells. Lung Cancer 2005, 49:337-343.
15. Kohno K., Sato S., Takano H., Matsuo K., Kuwano M. The direct activation of human multidrug resistance gene (MDR1) by anticancer agents. Biochem. Biophys. Res. Commun. 1989, 165:1415-1421.
16. Lagas J.S., van Waterschoot R.A., van Tilburg V.A., Hillebrand M.J., Lankheet N., Rosing H., Beijnen J.H., Schinkel A.H. Brain accumulation of dasatinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by elacridar treatment. Clin. Cancer Res. 2009, 15:2344-2351.
17. Maitra R., Halpin P.A., Karlson K.H., Page R.L., Paik D.Y., Leavitt M.O., Moyer B.D., Stanton B.A., Hamilton J.W. Differential effects of mitomycin C and doxorubicin on P-glycoprotein expression. Biochem. J. 2001, 355:617-624.
18. Minotti G. NADPH- and adriamycin-dependent microsomal release of iron and lipid peroxidation. Arch. Biochem. Biophys. 1990, 277:268-276.
19. Minotti G., Menna P., Salvatorelli E., Cairo G., Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev. 2004, 56:185-229.
20. Oda Y., Matsumoto Y., Harimaya K., Iwamoto Y., Tsuneyoshi M. Establishment of new multidrug-resistant human osteosarcoma cell lines. Oncol. Rep. 2000, 7:859-866.
21. Ohkawa H., Ohishi N., Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal. Biochem. 1979, 95:351-358.
22. Okabe M., Unno M., Harigae H., Kaku M., Okitsu Y., Sasaki T., Mizoi T., Shiiba K., Takanaga H., Terasaki T., Matsuno S., Sasaki I., Ito S., Abe T. Characterization of the organic cation transporter SLC22A16: a doxorubicin importer. Biochem. Biophys. Res. Commun. 2005, 333:754-762.
23. Rohde L.E., Bello-Klein A., Pereira R.P., Mazzotti N.G., Geib G., Weber C., Silva L.F., Clausell N. Superoxide dismutase activity in adriamycin-induced cardiotoxicity in humans: a potential novel tool for risk stratification. J. Card. Fail. 2005, 11:220-226.
24. Saad S.Y., Najjar T.A., Al-Rikabi A.C. The preventive role of deferoxamine against acute doxorubicin-induced cardiac, renal and hepatic toxicity in rats. Pharmacol. Res. 2001, 43:211-218.
25. Sauter K.A., Magun E.A., Iordanov M.S., Magun B.E. ZAK is required for doxorubicin, a novel ribotoxic stressor, to induce SAPK activation and apoptosis in HaCaT cells. Cancer Biol. Ther. 2010, 10:258-266.
26. Schinkel A.H., Smit J.J., van Tellingen O., Beijnen J.H., Wagenaar E., van Deemter L., Mol C.A., van der Valk M.A., Robanus-Maandag E.C., te Riele H.P., et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994, 77:491-502.
27. Schinkel A.H., Wagenaar E., Mol C.A., van Deemter L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J. Clin. Invest. 1996, 97:2517-2524.
28. Shi Y., Moon M., Dawood S., McManus B., Liu P.P. Mechanisms and management of doxorubicin cardiotoxicity. Herz 2011, 36:296-305.
29. Solbach T.F., Konig J., Fromm M.F., Zolk O. ATP-binding cassette transporters in the heart. Trends Cardiovasc. Med. 2006, 16:7-15.
30. Solbach T.F., Paulus B., Weyand M., Eschenhagen T., Zolk O., Fromm M.F. ATP-binding cassette transporters in human heart failure. Naunyn Schmiedebergs Arch. Pharmacol. 2008, 377:231-243.
31. Takemura G., Fujiwara H. Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management. Prog. Cardiovasc. Dis. 2007, 49:330-352.
32. Tiwari A.K., Sodani K., Wang S.R., Kuang Y.H., Ashby C.R., Chen X., Chen Z.S. Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters. Biochem. Pharmacol. 2009, 78:153-161.
33. van Asperen J., van Tellingen O., Tijssen F., Schinkel A.H., Beijnen J.H. Increased accumulation of doxorubicin and doxorubicinol in cardiac tissue of mice lacking mdr1a P-glycoprotein. Br. J. Cancer 1999, 79:108-113.
34. van Waterschoot R.A., Lagas J.S., Wagenaar E., van der Kruijssen C.M., van Herwaarden A.E., Song J.Y., Rooswinkel R.W., van Tellingen O., Rosing H., Beijnen J.H., Schinkel A.H. Absence of both cytochrome P450 3A and P-glycoprotein dramatically increases docetaxel oral bioavailability and risk of intestinal toxicity. Cancer Res. 2009, 69:8996-9002.
35. Villar V.H., Vogler O., Martinez-Serra J., Ramos R., Calabuig-Farinas S., Gutierrez A., Barcelo F., Martin-Broto J., Alemany R. Nilotinib counteracts P-glycoprotein-mediated multidrug resistance and synergizes the antitumoral effect of doxorubicin in soft tissue sarcomas. PLoS One 2012, 7:e37735.
36. Weisberg E., Manley P.W., Breitenstein W., Bruggen J., Cowan-Jacob S.W., Ray A., Huntly B., Fabbro D., Fendrich G., Hall-Meyers E., Kung A.L., Mestan J., Daley G.Q., Callahan L., Catley L., Cavazza C., Azam M., Neuberg D., Wright R.D., Gilliland D.G., Griffin J.D. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005, 7:129-141.
37. Zuppinger C., Timolati F., Suter T.M. Pathophysiology and diagnosis of cancer drug induced cardiomyopathy. Cardiovasc. Toxicol. 2007, 7:61-66.